SAMHD1 and acute myeloid leukemia: Active SAMHD1 catalyzes the hydrolysis and inactivation of a number of different nucleoside analogues [30,31], including cytarabine (Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous leukaemia (AML) and SAMHD1 expression levels were negatively correlated with Ara-C treatment success in individuals with AML [27,29,32].